6-APB

Not scheduled at the federal level. However, it may be considered an analogue of MDA, meaning purchase, sale, or possession with intent to consume could potentially be prosecuted under the Federal Analogue Act.⁷⁶ Several states have independently scheduled it: Florida and Louisiana list it as Schedule I (2013),⁷⁷⁷⁸ Minnesota added it to Schedule I in 2012,⁷⁹ and Wisconsin classified it as Schedule I in 2018.⁸⁰

As of 28 August 2026, the current Normattiva view of D.P.R. 309/1990 is marked vigente al 28/08/2026 and records the act's latest published update as 06/08/2026. Its current Tabella I (Tabelle, parte 1) expressly lists 6-APB with the chemical designation 6-(2-aminopropil)benzofurano. The Ministry of Health's Decreto 25 June 2013 inserted 6-APB into Tabella I; it entered into force on the fifteenth day after publication (23 July 2013). Accordingly, 6-APB is an expressly scheduled narcotic/psychotropic substance, not merely an analogue or catch-all case. Unauthorized cultivation, production, manufacture, extraction, refining, sale, offering, transfer, distribution, commerce, transport, procurement, sending, transit or delivery of a Tabella I substance is subject to D.P.R. 309/1990 art. 73(1): imprisonment from six to twenty years and a fine of EUR 26,000 to EUR 260,000. Import, export, acquisition, receipt or possession that appears intended for use other than exclusively personal is covered by art. 73(1-bis) and the same penalties; statutory indicators include quantity, presentation/packaging and other circumstances, so no universal quantity rule decides every case. Art. 73(5) provides the lower-level offence range (six months to five years and EUR 1,032 to EUR 10,329), while a non-occasional low-level conduct is 18 months to five years and EUR 2,500 to EUR 10,329. Possession, acquisition, import or export for exclusively personal use is handled separately as an administrative offence under art. 75: for Table I substances, one or more sanctions may apply for two months to one year (including suspension or denial of driving credentials, firearms licence, passport/equivalent documents, and for a non-EU citizen a tourism residence permit). Police may immediately withdraw a licence for 30 days when a motor vehicle is directly available, and the prefect decides the administrative sanction after the statutory procedure. The art. 75 distinction is fact-dependent; personal-use treatment does not legalize 6-APB, and non-personal-purpose circumstances can trigger art. 73 criminal liability. The decree's 2013 recital states that no medical use or pharmaceutical preparation was approved at that time; the schedule itself does not create an authorization for possession or supply. Individual charging, sentencing, aggravation, and exceptions under authorization/research provisions remain case-specific.

As of 28 August 2026, the inspected official Luxembourg controlled-substance schedules support an unscheduled/not-expressly-listed result for the identified pure 6-APB compound. The current 1974 psychotropic Annex is applicable from 13 July 2026 and ends at item 66; the latest amendment (signed 6 July 2026, published 9 July 2026, effective 13 July 2026) adds only 2-MMC, NEP and 4-BMC. The separate narcotics list is current through 12 December 2025, and the 1997 regulation for Convention Tables III and IV is also current through 12 December 2025; neither contains 6-APB, its chemical name, CAS 286834-85-3, or an applicable generic benzofuran/amphetamine analogue rule. Article 1 of the 1974 psychotropic regulation extends coverage to stereoisomers of substances that are actually listed and certain naturally containing organisms/biological material; it does not create a general analogue or benzofuran-class rule. Article 7 of the 1973 law penalizes illicit use or personal transport, possession or acquisition only of substances determined by grand-ducal regulation, while Article 8 provides one-to-five years' imprisonment and a €500-€1,250,000 fine (or either) for illicit trafficking-type acts involving substances within Article 7. Those penalty provisions are therefore not assigned to 6-APB solely on the schedules reviewed. Unscheduled is not an affirmative declaration that every product, mixture, medicinal claim, toxic-substance classification, import, sale, or use is lawful; this dossier addresses the identified pure compound under the national controlled-substance schedules inspected, and fact-specific or later legislative changes may alter the result.

The supplied legacy note is supported with a necessary qualification: 6-APB should not be treated as lawful merely because its name is absent from the named schedules. Section 2(1) defines a controlled drug analogue as a substance having a structure substantially similar to any controlled drug and includes such analogues in Class C; the definition excludes substances already specified in Schedules 1 or 2 or Schedule 3 Parts 1-6, pharmacy-only/prescription/restricted medicines under the Medicines Act 1981, approved Psychoactive Substances Act 2013 products, and non-psychoactive THC analogues. PubChem identifies 6-APB as 1-(1-benzofuran-6-yl)propan-2-amine (6-(2-aminopropyl)benzofuran), an amphetamine-type alpha-methyl phenethylamine with a benzofuran ring. Schedule 3 Part 7 describes amphetamine analogues with the 1-amino-2-phenylethane nucleus and qualifying ring radicals, but the fused benzofuran oxygen arrangement means the Part 7 mapping should be stated as structural context rather than an unqualified exact-listing conclusion; the independent section 2 substantial-similarity rule is the controlling analogue route. On that evidence, the appropriate canonical result is analog_covered/Class C, not unscheduled or legal. Sections 6 and 7 prohibit unauthorised import/export, production/manufacture, supply and possession/use of controlled drugs, subject to section 8, licences and regulations. New Zealand Police summarises the Class C maximum as 3 months' imprisonment and/or a $500 fine for possession, and for supply or manufacture up to 8 years on indictment or 1 year and/or $1,000 summarily; the charge, conduct and facts govern. Section 29C provides a limited defence to possession of a controlled-drug analogue where the defendant proves a non-consumption/non-supply purpose, or supply/administration under a Director-General of Health-approved procedure. The 2026 classification order was inspected for later named additions and does not name 6-APB; no separate presumed-supply threshold for it is asserted. This is a structure-specific legal classification, not a claim that every salt, mixture, misidentified product, medicinal product or approved psychoactive product is covered identically; a forensic identity and legal determination remain material.

As of 28 August 2026, 6-APB is expressly listed by name in the annex to Council of Ministers Decision No. 2013/5742 as a substance subject to Law No. 2313. The decision identifies it as the substance known as 6-APB, 6-(2-aminopropyl)benzofuran, and was made under Article 19 after a Health Ministry proposal. Law No. 2313 control is the identity/control rule; the 13 June 2026 Official Gazette (No. 33279) still lists the later Decision No. 11418 under the same statutory mechanism and does not repeal the 2013/5742 listing. Unlicensed manufacture, import or export is punishable under Turkish Penal Code Article 188(1) by 20–30 years' imprisonment and 2,000–20,000 days' judicial fine. Unlicensed domestic sale, offering for sale, giving to another, shipment, transport, storage, purchase, acceptance or possession is punishable under Article 188(3) by at least 10 years' imprisonment and 1,000–20,000 days' judicial fine; the child-recipient minimum is 15 years. Article 188(4)(a) increases the penalty by one half when the substance is legally characterized as an amphetamine derivative, among the listed aggravating categories; application to a particular 6-APB sample is fact- and forensic-characterization dependent. Purchase, acceptance, possession or use for personal use falls under Article 191(1), carrying 2–5 years' imprisonment; Article 191(2)-(3) ordinarily provides a five-year deferral of public prosecution with at least one year of probation, extendable by up to two additional years, and possible treatment, subject to statutory breaches and case facts. The scheduling entry does not create a safe research-chemical or personal-use exception; licensed scientific/medical handling, if any, requires the separate permissions contemplated by Turkish narcotics law. This is a legal-status summary, not a prediction of charge or sentence in an individual case.

As at 27 August 2026, the Federal Register marks the June 2026 Poisons Standard as in force from 1 June 2026. Its Schedule 9 is the prohibited-substances schedule, but searches of the current Schedule 9 for 6-APB, 1-(benzofuran-6-yl)propan-2-amine and benzofuran found no explicit entry. The Poisons Standard explanatory statement says its Schedules are incorporated by reference in State and Territory legislation and do not have direct application in their own right, so domestic possession, manufacture, supply and use rules and penalties must be checked in the applicable State or Territory. Federal control is nevertheless explicit: Customs regulation 5 prohibits importing a drug unless the importer has both an import licence and drug-specific permission, produces the permission, imports during its period and stays within its quantity, subject to the regulation's approval and prescribed-medical passenger exceptions. Customs Schedule 4 item 19A names 6-APB. Criminal Code Regulations Schedule 1 item 24 sets controlled-drug quantities at 0.75 kg commercial, 250 g marketable and 0.75 g trafficable; Schedule 2 item 20 sets border-controlled quantities at 0.75 kg commercial and 0.5 g marketable. Criminal Code section 308.1 provides a federal possession maximum of 2 years or 400 penalty units (or both); sections 302.2–302.4 provide controlled-drug trafficking maxima of life/7,500 units for commercial, 25 years/5,000 units for marketable, or 10 years/2,000 units otherwise (or both). Sections 307.1–307.3 provide the same three maxima for importing or exporting border-controlled drugs, while section 307.4 provides 2 years or 400 penalty units (or both) where the no-commercial-intent defence is unavailable for a non-determined border-controlled drug. The Crimes (Amount of a Penalty Unit) Instrument 2026 sets one unit at $364 for offences committed on or after 1 July 2026, so the general federal possession/no-commercial-intent maximum is $145,600 and the import or trafficking fine maxima are $2,730,000, $1,820,000 and $728,000 respectively. These are Commonwealth maxima and do not replace State or Territory offences.

As of 28 August 2026, Finland's operative narcotics schedule is Government Decree 543/2008 as most recently amended for Annexes I, II and IV by Government Decree 1119/2025, effective 29 December 2025. Annex IV expressly lists 6-(2-Aminopropyyli)bentsofuraani (6-APB) with the chemical identity 1-(1-bentsofuran-6-yyli)propaani-2-amiini. Section 1 of Decree 543/2008 provides that substances, preparations and plants listed in Annexes I–IV are narcotics; the 2025 amendment replaced the annex text rather than removing this entry. Under the Narcotics Act, narcotics include substances in the relevant convention lists and the detailed list is set by Government decree. Production, manufacture, import, export, transport, transit, distribution, trade, handling, possession and use are prohibited, subject only to separately regulated medical, research and supervisory exceptions. Unlawful manufacture, import/export/transport, sale/distribution, possession or attempted acquisition is a Chapter 50 section 1 narcotics offence punishable by a fine or up to two years' imprisonment. Unlawful use, or possession/attempted acquisition of a small amount for personal use, is a section 2 a use offence punishable by a fine or up to six months' imprisonment; the statutory possibility to waive prosecution or punishment for a minor offence or treatment referral is fact-dependent. Where a Chapter 50 section 2 aggravating condition applies and the offence is also overall serious, aggravated narcotics offence carries one to ten years' imprisonment. The schedule listing makes 6-APB a prohibited narcotic; it does not itself establish a fixed quantity threshold or guarantee a particular charge, sentence or treatment disposition in an individual case.

The old NPS-list framing is no longer current. Portaria 232/2022 expressly identifies 6-APB as removed from the NPS list because it was added to Table II-B of Decreto-Lei 15/93, effective 8 September 2022. The resulting ordinary status is prohibited: Article 21(1) covers unauthorized production, supply, trafficking and illicit possession of substances in Tables I-III, while preserving the authorization element. Portugal's decriminalization is not legalization: Article 40 treats acquisition or detention for exclusive own consumption as a contraordenação; more than the 10-day average is an evidentiary indication, not an automatic trafficking finding, and proven exclusive own use can lead to archiving, non-indictment or acquittal with referral. Own-use cultivation remains separately punishable, with possible waiver of penalty. No claim is made that the former NPS regime still applies to 6-APB.